Articles

In this exclusive interview, Melissa Paige, Chief Executive Officer and Founder, Paige Consulting, LLC, Charlottesville, VA, and Infusion/Oncology Patient Access Principal Coordinator at a large academic center, shares her experience in helping patients with cancer obtain access to oral and infused therapies. Read More ›

The Centers for Medicare & Medicaid Services (CMS) has announced an expansion of coverage for telehealth services for Medicare beneficiaries. To qualify, 2-way real-time interactive communication between providers and patients using both audio and video technology is required. Read More ›

Remote patient monitoring, in which digital technologies are used to detect changes in vital signs or symptoms, may offer a convenient way to signal the need for a change in management, thereby potentially improving outcomes. Read More ›

According to data from the National Cancer Institute, approximately 1.2% of women in the United States will be diagnosed with ovarian cancer at some point in their lifetime. It is estimated that more than 20,000 women will be diagnosed with ovarian cancer in 2020, and nearly 14,000 women will die from the disease in the same year. Most deaths will occur in women aged >55 years. Read More ›

The COVID-19 pandemic will have far-reaching economic implications in the United States and abroad for the foreseeable future. During this session, Murray Aitken, MBA, Director, IQVIA Institute, presented emerging data regarding some of the ways in which the pandemic is affecting the US economy. Read More ›

Burt Zweigenhaft, PhD, D.Litt, Founder, Association for Value-Based Cancer Care, moderated a panel session in which 3 experts from the independent actuarial firm, Milliman, discussed recent data showing the ways in which the COVID-19 pandemic may affect the future of healthcare. Read More ›

On May 26, 2020, the FDA approved nivolumab (Opdivo; BMS) and ipilimumab (Yervoy; BMS) plus chemotherapy as first-line treatment of recurrent or metastatic squamous or nonsquamous non–small-cell lung cancer (NSCLC), regardless of PD-L1 expression, and with no EGFR or ALK aberrations. On May 15, the FDA approved nivolumab plus ipilimumab as first-line treatment of metastatic NSCLC with PD-L1 ≥1% expression. Read More ›

On May 29, 2020, the FDA approved the immunotherapy atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, in combination with bevacizumab (Avastin; Genentech), a vascular endothelial growth factor inhibitor, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received systemic therapy. This is the first immunotherapy regimen approved by the FDA for this type of HCC. Read More ›

Lymphomas are a heterogeneous group of malignancies that are associated with substantial morbidity and mortality. Although standard chemoimmunotherapy regimens lead to durable remissions in a substantial proportion of patients, many individuals will relapse and develop refractory disease. Therefore, a clear need exists for the development of novel therapies that are designed to treat relapsed/refractory B-cell malignancies. Read More ›

The development and utilization of novel therapies, including small-molecule agents, have undoubtedly altered the treatment landscape for many indolent non-Hodgkin B-cell malignancies in the frontline and relapsed/ refractory settings. The availability of such agents as Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase (PI3K) inhibitors addresses an unmet need among oncologists and advanced practice providers (APPs) who are seeking additional therapeutic options for their patients, particularly those with relapsed/refractory disease. Read More ›